aap reports first-half year organic increase in sales of 29%

Berlin, July 2, 2008

aap Implantate AG, a medical technology company listed on the
Frankfurt Stock Exchange in the Prime Standard segment and active in
medical biomaterials, fracture healing and joint replacement,
achieved in the first six months of the financial year 2008 -
according to preliminary figures - a sales growth of 29% to EUR 16.4
million (first half of 2007: EUR 12.7 million).

Sales growth was mainly achieved by the above-average development of
the trauma & orthopaedics segment of aap (+80% to EUR 7.0 million)
while the aap bio implants group, which specialises in medical
biomaterials, showed a sales growth of approx. 7% to EUR 9.4 million.
aap expects considerably double-digit growth rates for the
biomaterials segment during the second half of the year.

+---------------------------------------------------------+
| In EUR million | 2008 | 2007 | Change |
|----------------------------------+------+------+--------|
| Sales 1st half year | 16.4 | 12.7 | +29% |
|----------------------------------+------+------+--------|
| -thereof Trauma & Orthopaedics | 7.0 | 3.9 | +80% |
|----------------------------------+------+------+--------|
| - thereof aap bio implants group | 9.4 | 8.8 | +7% |
+---------------------------------------------------------+

For 2008 aap anticipates an organic sales growth of more than 20%,
with above-average impact on the company's operating result and net
income. The publication of the full aap Implantate AG six month
report 2008 is scheduled for August 13, 2008.

-
aap is a medical technology company that develops, manufactures and
markets biomaterials and implants for trauma and orthopaedics. Its
product portfolio includes bone cements, bone graft substitutes,
antibiotic carriers, and implants for fracture healing and joint
replacement. In addition to its Berlin headquarters the company has
locations in Dieburg and Obernburg near Frankfurt am Main, Düsseldorf
as well as at Nijmegen in the Netherlands. aap Implantate AG has been
listed in the Prime Standard segment at the Frankfurt stock exchange
since May 16, 2003.

Please address any queries to:
aap Implantate AG, Nanette Hüdepohl, Head of Corporate
Communications, Lorenzweg 5, 12099 Berlin, Germany
Tel.: +49 30 7501 9133; Fax: +49 30 7501 9290; n.huedepohl@aap.de

For further information about aap bio implants, visit
www.aap-bioimplants.com
Copyright © Hugin AS 2008. All rights reserved.